FDA approves Mylan blood pressure drug

The FDA has approved Mylan Laboratories Nebivolol for high blood pressure contingent on Mylan's submission of preclinical data and the resolution of labeling requirements. The approvable letter comes slightly more than a year after the drug company filed its NDA. Mylan representatives say the data from an ongoing preclinical study of the beta blocker should satisfy the agency. Mylan licensed Nebivolol from Janssen Pharmaceutica four years ago.

- read this story from MSN for more on the approval

ALSO: Carl Icahn has dropped his lawsuit against Richard Perry, who had supported Mylan's failed bid to buy King Pharmaceuticals. Article

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.